Regeneron Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All 0R2M.L news ›Regeneron Pharmaceuticals, Inc. Announces Libtayo® Recommended For EU Approval By The CHMP For Updated Dosing Regimen Across All Approved Cancer Types
Regeneron Pharmaceuticals, Inc. announced that the European Medicines Agency?s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of an... announced that the European Medicines Agency?s…
What to Expect From Regeneron Pharmaceuticals' Next Quarterly Earnings Report
Barchart.com
2,281 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by First Citizens Bank & Trust Co.
Posted by Defense World Staff on Oct 16th, 2026 First Citizens Bank & Trust Co. bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the third quarter, according to the company in its most…
Regeneron Pharmaceuticals, Inc. $REGN Stock Sold by Curated Wealth Partners LLC
MarketBeat Regeneron Pharmaceuticals, Inc. $REGN Stock Sold by Curated Wealth Partners LLC - Curated Wealth Partners cut its Regeneron stake by 96.3% in the third quarter, selling 35,373 shares and retaining 1,365 shares worth…
UBS Upgrades Regeneron Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $978 From $660
Regeneron Pharmaceuticals has an average rating of overweight and mean price target of $869.08, according to analysts polled by FactSet. Price: 795.02, Change: +16.66, Percent Change: +2.14 ... Published on 10/15/2026 at 10:38 am EDT…
UBS Upgrades Regeneron Pharmaceuticals (REGN) on Next-Gen Dupixent Potential
On October 14, 2026, UBS upgraded Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to a Buy rating, citing undervaluation in the market related to the company’s promising pipeline of successors to its blockbuster drug Dupixent. The firm set a…
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $968 From $972
marketscreener.com Published on 10/15/2026 at 06:32 am EDT Regeneron's Yancopoulos on Hearing Loss Gene Therapy, Weight Loss Drugs January 13, 2026 at 04:08 pm EST
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Up 3.6% - Here's What Happened
MarketBeat Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Up 3.6% - Here's What Happened - Regeneron shares rose 3.6% to about $780.49, although trading volume was 54% below the average session volume. - Analysts remain broadly…
Regeneron Pharmaceuticals, Inc. Announces Positive 84-Week Results From Phase 3 OPTIMA Trial Evaluating Pasatru In Adults With Fibrodysplasia Ossificans Progressiva
Published on 10/12/2026 at 05:43 pm EDT The endpoints were then re-assessed at 84 weeks. From week 56, there were no new HO lesions observed at week 84 for Pasatru compared to 9 new lesions for placebo as assessed by computed tomography…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com15
-
marketbeat.com9
-
gurufocus.com4
-
defenseworld.net3
-
moomoo.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 43 articles, not a forecast.